A popular supplement may have just picked up a surprising new mechanism: calming the cells that make your platelets. But the study was done in mice and lab-grown cells, not people, and that matters a lot.
A new paper in Aging Cell reports that coenzyme Q10 (CoQ10) improved the function of aged megakaryocytes in mice. Megakaryocytes are the large bone marrow cells that produce platelets. The treated animals also showed less platelet aggregation and activation. Here is what was found, what it does and doesn't mean, and who should be cautious.
The Big Idea: Old Platelet Factories Misfire
Platelets are the tiny cell fragments that help blood clot. As we age, the cells that make them can become dysfunctional, and platelets can become "hyperreactive," meaning they clump and activate more readily. The authors note that this age-related megakaryocyte dysfunction may increase thrombotic (clotting) risk.
What was unclear, according to the researchers, was whether CoQ10 could restore megakaryocyte health, and whether autophagy might be involved. Autophagy is the cell's internal recycling system, which clears damaged components.
What the Researchers Actually Did
The team gave CoQ10 for 12 weeks to male C57BL/6J mice at several ages: 1, 9, 15, 19, 21, and 23 months. They then examined bone marrow megakaryocytes and platelet behavior. They also used a human megakaryocyte-like cell line (MEG-01) pushed into a senescent, "aged" state with hydrogen peroxide. This let them test the mechanism with drugs that turn autophagy up or down and with gene knockdown.
The Headline Findings
- Better megakaryocyte function in aged mice. CoQ10 enhanced megakaryocyte proliferation, maturation, and polyploidization (the DNA multiplication step these cells go through as they mature).
- Signs of boosted autophagy. Shifts in the markers LC3-II/LC3-I and p62 were consistent with enhanced autophagy in bone marrow megakaryocytes.
- A new player: COPS3. Proteomic analysis found higher COPS3 levels in megakaryocytes from CoQ10-treated 24-month-old mice.
- Calmer platelets. CoQ10 did not change platelet counts in naturally aged mice, but it was associated with reduced platelet aggregation and activation.
The Mechanism: Where COPS3 Fits
In the senescent MEG-01 cells, the responses to rapamycin and LY294002 supported the idea that autophagy-related signaling is involved in CoQ10's effects. CoQ10 also increased COPS3 expression even under autophagy-inhibiting conditions. Flux assays using bafilomycin A1 showed greater LC3-II accumulation, which supports increased autophagic flux and not just a buildup of unprocessed material.
When the researchers knocked down COPS3, CoQ10's effects on autophagy markers were attenuated, and its effects on megakaryocyte maturation and polyploidization were partially reduced. So COPS3 appears to contribute but is not the whole story. The authors say it "may not solely mediate" the responses, and that CoQ10 works "in part" through COPS3-associated autophagy regulation.
Why This Is Not a Clot-Prevention Claim
This is where hype needs a brake.
- Mouse and cell work only. The paper contains no human data.
- Male mice only. Findings may not carry over to females or to people.
- No clot outcomes. The paper reports reduced platelet aggregation and activation as markers. It does not show that CoQ10 prevented clots, heart attacks, or strokes.
- Platelet counts didn't change. The effect was on how platelets behave, not how many there are.
- Mechanism is partial. Knocking down COPS3 only partly blunted the effects, so other pathways are likely involved.
The authors frame their work as a "mechanistic basis for further investigation" of CoQ10 as a nutritional strategy for age-related platelet dysfunction. That is a research direction, not a treatment recommendation.
Practical Takeaways
Doses and forms. The abstract does not report the mouse dose, and animal doses don't translate directly to humans, so there is no evidence-based human dose to extract from this paper. Commercial CoQ10 is typically sold as ubiquinone or ubiquinol softgels, often labeled to be taken with a meal containing fat because the compound is fat-soluble. Product strengths vary widely, so read labels and ask a clinician what, if anything, suits you.
Who might be curious. Adults interested in healthy-aging research who already discuss supplements with their healthcare provider may find this a useful signal to watch. It is not a reason to start taking CoQ10 to "thin" or "normalize" your blood.
Who should skip or check first.
- Anyone on blood thinners or antiplatelet drugs (such as warfarin, apixaban, rivaroxaban, clopidogrel, or aspirin) should talk to a doctor or pharmacist before adding CoQ10. This study suggests CoQ10 may affect platelet behavior in mice, and combining supplements with medications that act on clotting deserves professional oversight.
- People with bleeding disorders, those awaiting surgery, and people with a history of clots or cardiovascular disease should also get medical advice first.
- Pregnant or breastfeeding individuals and people on multiple medications should consult a clinician before starting any new supplement.
- Never stop or change a prescribed anticoagulant or antiplatelet drug on the strength of a mouse study.
The Bottom Line
This study offers an intriguing look at how a well-known antioxidant-related compound might help aged platelet-producing cells in mice, possibly by reviving autophagy through COPS3. It is early, preclinical science. The real test will be whether controlled human studies show that CoQ10 changes platelet function, and whether that translates into any meaningful clinical benefit.